 Advancing Dyadic s proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial To validate C1 produced proteins are safe in humans and accelerate C1 adoption and commercialization To serve as proof of concept for next-generation multivalent COVID-19 vaccine candidates Expanded Korea and Southeast Asia vaccine development partnership with Medytox 086900 KOSDAQ focused on next-generation COVID-19 variant vaccines andor boosters In parallel with DYAI-100, additional proprietary and third-party COVID-19 variant vaccine candidates are under development Developing a number of other infectious disease vaccines and antibodies internally and in conjunction with others Expanding commercial opportunities of C1 technology through eleven new and two expanded collaborations for human and animal health applications C1 selected by ZAPI Zoonosis Anticipation Preparedness Initiative as a vaccine manufacturing platform for more efficient production of antigens that are safe, effective, and protective Cash and investment grade securities of 29.2 million at year-end 2020 JUPITER, FL ACCESSWIRE March 30, 2020 Dyadic International, Inc. Dyadic, we, us, our, or the Company NASDAQ:DYAI, a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs and other commercial products at flexible commercial scales, today announced its financial results for 2020 and recent business highlights. We are very pleased with substantial progress made thus far in 2021 and over the course of 2020. 